Literature DB >> 23555184

Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes.

Ludivine Coudière Morrison1, Robyn McClelland, Christopher Aiken, Melissa Bridges, Lisa Liang, Xin Wang, Domenico Di Curzio, Marc R Del Bigio, Michael D Taylor, Tamra E Werbowetski-Ogilvie.   

Abstract

Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor. Major research efforts have focused on characterizing and targeting putative brain tumor stem or propagating cell populations from the tumor mass. However, less is known about the relationship between these cells and highly invasive MB cells that evade current therapies. Here, we dissected MB cellular heterogeneity and directly compared invasion and self-renewal. Analysis of higher versus lower self-renewing tumor spheres and stationary versus migrating adherent MB cells revealed differential expression of the cell surface markers CD271 [p75 neurotrophin receptor (p75NTR)] and CD133. Cell sorting demonstrated that CD271 selects for subpopulations with a higher capacity for self-renewal, whereas CD133 selects for cells exhibiting increased invasion in vitro. CD271 expression is higher in human fetal cerebellum and primary samples of the Shh MB molecular variant and lower in the more aggressive, invasive group 3 and 4 subgroups. Global gene expression analysis of higher versus lower self-renewing MB tumor spheres revealed down-regulation of a cell movement transcription program in the higher self-renewing state and a novel potential role for axon guidance signaling in MB-propagating cells. We have identified a cell surface signature based on CD133/CD271 expression that selects for MB cells with a higher self-renewal potential or invasive capacity in vitro. Our study underscores a previously unappreciated role for CD271 in selecting for MB cell phenotypes and suggests that successful treatment of pediatric brain tumors requires concomitant targeting of a spectrum of transitioning self-renewing and highly infiltrative cell subpopulations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23555184      PMCID: PMC3612911          DOI: 10.1593/neo.13148

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  49 in total

1.  Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma.

Authors:  Tracy-Ann Read; Marie P Fogarty; Shirley L Markant; Roger E McLendon; Zhengzheng Wei; David W Ellison; Phillip G Febbo; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

2.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.

Authors:  Zeng-Jie Yang; Tammy Ellis; Shirley L Markant; Tracy-Ann Read; Jessica D Kessler; Melissa Bourboulas; Ulrich Schüller; Robert Machold; Gord Fishell; David H Rowitch; Brandon J Wainwright; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

Review 3.  Multiple roles of the p75 neurotrophin receptor in the nervous system.

Authors:  Y Chen; J Zeng; L Cen; Y Chen; X Wang; G Yao; W Wang; W Qi; K Kong
Journal:  J Int Med Res       Date:  2009 Mar-Apr       Impact factor: 1.671

4.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Authors:  Hui Miao; Da-Qiang Li; Amitava Mukherjee; Hong Guo; Aaron Petty; Jennifer Cutter; James P Basilion; John Sedor; Jiong Wu; David Danielpour; Andrew E Sloan; Mark L Cohen; Bingcheng Wang
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

5.  Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma.

Authors:  Ryan J Ward; Lilian Lee; Kevin Graham; Thevagi Satkunendran; Koichi Yoshikawa; Erick Ling; Lauren Harper; Ryan Austin; Erica Nieuwenhuis; Ian D Clarke; Chi-Chung Hui; Peter B Dirks
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

6.  Expression of p75NTR in fetal brain and medulloblastomas: evidence of a precursor cell marker and its persistence in neoplasia.

Authors:  Michael Barnes; Charles G Eberhart; Rodney Collins; Tarik Tihan
Journal:  J Neurooncol       Date:  2008-12-09       Impact factor: 4.130

7.  CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells.

Authors:  Jan Pruszak; Wesley Ludwig; Alexandra Blak; Kambiz Alavian; Ole Isacson
Journal:  Stem Cells       Date:  2009-12       Impact factor: 6.277

Review 8.  The increasing complexity of the cancer stem cell paradigm.

Authors:  Jeffrey M Rosen; Craig T Jordan
Journal:  Science       Date:  2009-06-26       Impact factor: 47.728

9.  Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.

Authors:  Ulrich Schüller; Vivi M Heine; Junhao Mao; Alvin T Kho; Allison K Dillon; Young-Goo Han; Emmanuelle Huillard; Tao Sun; Azra H Ligon; Ying Qian; Qiufu Ma; Arturo Alvarez-Buylla; Andrew P McMahon; David H Rowitch; Keith L Ligon
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

10.  Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.

Authors:  LiMei Wang; Jennifer J Rahn; XueQing Lun; Beichen Sun; John J P Kelly; Samuel Weiss; Stephen M Robbins; Peter A Forsyth; Donna L Senger
Journal:  PLoS Biol       Date:  2008-11-25       Impact factor: 8.029

View more
  22 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.

Authors:  Emma Sandén; Cecilia Dyberg; Cecilia Krona; Edward Visse; Helena Carén; Paul A Northcott; Marcel Kool; Nils Ståhl; Annette Persson; Elisabet Englund; John I Johnsen; Peter Siesjö; Anna Darabi
Journal:  J Neurooncol       Date:  2015-03-29       Impact factor: 4.130

3.  ASYMMETRIC CELL DIVISION: IMPLICATIONS FOR GLIOMA DEVELOPMENT AND TREATMENT.

Authors:  Kate Marie Lewis; Claudia Petritsch
Journal:  Transl Neurosci       Date:  2013-12       Impact factor: 1.757

4.  Salinomycin Suppresses PDGFRβ, MYC, and Notch Signaling in Human Medulloblastoma.

Authors:  Shuang Zhou; Fengfei Wang; Ying Zhang; Max R Johnson; Steven Qian; Min Wu; Erxi Wu
Journal:  Austin J Pharmacol Ther       Date:  2014

5.  Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression.

Authors:  Jamie Zagozewski; Stephanie Borlase; Brent J Guppy; Ludivine Coudière-Morrison; Ghazaleh M Shahriary; Victor Gordon; Lisa Liang; Stephen Cheng; Christopher J Porter; Rhonda Kelley; Cynthia Hawkins; Jennifer A Chan; Yan Liang; Jingjing Gong; Carolina Nör; Olivier Saulnier; Robert J Wechsler-Reya; Vijay Ramaswamy; Tamra E Werbowetski-Ogilvie
Journal:  Commun Biol       Date:  2022-07-14

Review 6.  Medulloblastoma development: tumor biology informs treatment decisions.

Authors:  Vidya Gopalakrishnan; Rong-Hua Tao; Tara Dobson; William Brugmann; Soumen Khatua
Journal:  CNS Oncol       Date:  2015

7.  In vitro formation of neuroclusters in microfluidic devices and cell migration as a function of stromal-derived growth factor 1 gradients.

Authors:  Sean McCutcheon; Uchenna Unachukwu; Ankush Thakur; Robert Majeska; Stephen Redenti; Maribel Vazquez
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

Review 8.  Extracellular Vesicles in Brain Tumor Progression.

Authors:  Esterina D'Asti; Shilpa Chennakrishnaiah; Tae Hoon Lee; Janusz Rak
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

9.  Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization.

Authors:  Shilpa Bhatia; Nimrah A Baig; Olga Timofeeva; Elena B Pasquale; Kellen Hirsch; Tobey J MacDonald; Anatoly Dritschilo; Yi Chien Lee; Mark Henkemeyer; Brian Rood; Mira Jung; Xiao-Jing Wang; Marcel Kool; Olga Rodriguez; Chris Albanese; Sana D Karam
Journal:  Oncotarget       Date:  2015-04-20

Review 10.  Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.

Authors:  Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares
Journal:  Curr Treat Options Oncol       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.